Press release
HomeSun files injunction to stop the coalition government cutting a further 25,000 jobs
Government ploughs ahead with job cuts as new unemployment figures are released.25,000 workers in the rapidly growing domestic renewable energy services sector are at risk of losing their jobs before Christmas due to the coalition government’s poorly thought-through FITs policy. At the same time, the Office of National Statistics has announced new unemployment figures showing an a rise of 129,000 in unemployment. These worrying statistics support The Chartered Institute of Personnel and Development’s report on Monday, which claims that the UK labour market faces a “slow, painful contraction” with firms delaying staff recruitment.
HomeSun has filed an injunction against the coalition government to stop them making another 25,000 unemployed.
Daniel Green, CEO of HomeSun says: “There is a desperate need for jobs in the UK and FITs has created 25,000 jobs and 3,000 enterprises. These jobs are nationwide and performed by young and old. It seems madness to be cutting this growing industry off at the knees and we are going to fight it all the way to court on two counts:
1. that the government consultation is a sham because it has already decided to change the tariff from 12th December. Making decisions before the end of the consultation period on 23rd December indicates that the decision is a foregone conclusion and makes a mockery of the consultation process
2. that the 12 December cut-off date is irrationally short, since it fails to provide the industry with reasonable time to re-orient their businesses to a reduced tariff.
“The coalition government’s argument is that at current levels the FITS budget will run out too soon, but FITs generates in excess of £280 million from taxes and VAT, whereas the cost has only been £220 million. That’s a net profit of £50 million but it seems that the Treasury and DECC are not talking.
“In addition to throwing away £50 million, the Department of Work and Pensions will have to spend millions in unemployment benefit for all the thousands of people who will lose their jobs and investor confidence in what was a growing sector will be destroyed.”
Visit http://www.homesun.com/ for more information
HomeSun was the first company to install and maintain solar PV panels nationwide at no upfront cost to householders and are now the largest. The HomeSun ‘free solar’ business model has reduced household electricity bills by around one third and made solar an option for those who would not otherwise consider it because of cost or payback time.
Totally Communications
Unit 800 Highgate Studios
53-79 Highgate Road
London
NW5 1TL
Adam Shore
adam@totallycommunications.com
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release HomeSun files injunction to stop the coalition government cutting a further 25,000 jobs here
News-ID: 202316 • Views: …
More Releases for HomeSun
Homesun Solar Tells You: Residential vs. Commercial Solar Systems: 5 Key Differe …
One of the renewable energy sources with the quickest rate of growth in the world today is solar power. Going solar is a wise move, regardless of whether you're a business owner trying to lower operating costs and your carbon footprint or a homeowner hoping to lower electricity bills. But not every solar system is the same. Depending on whether a solar system is being installed for a residential or…
Ticlopidine Market Size, Share and Forecast By Key Players-MENOVO, Homesun Pharm …
𝐔𝐒𝐀, 𝐍𝐞𝐰 𝐉𝐞𝐫𝐬𝐞𝐲- According to the MRI Team's Market Research Intellect, the global Ticlopidine market is anticipated to grow at a compound annual growth rate (CAGR) of 16.67% between 2024 and 2031. The market is expected to grow to USD 6.68 Billion by 2024. The valuation is expected to reach USD 19.66 Billion by 2031.
Due to the rising incidence of cardiovascular illnesses and the growing demand for efficient antiplatelet treatments, the ticlopidine market is…
Levofloxacin Hydrochloride Market to Witness Huge Growth by Key Players: Santa C …
Global Levofloxacin Hydrochloride Market 2021-2027, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects in the coming years. The report includes a discussion of the key vendors operating in this market. An exclusive data offered in this report is collected by research and industry experts team.
Get Free Sample PDF (including full TOC, Tables and Figures)…
Ticlopidine Market Growth and COVID-19 Impact Analysis 2021-2027 | MENOVO, Homes …
Ticlopidine is a potent platelet aggregation inhibitor. It's a prodrug that's metabolised into an active form, and it works by blocking the ADP receptor, which is involved in GPIIb/IIIa receptor activation, which causes platelet aggregation. Ticlopidine is sold under the brand name Ticlid and is used to treat patients who are unable to take aspirin or who have tried and failed to prevent a thrombotic stroke with aspirin.
Ticlopidine Market research…
Global Dexlansoprazole Market: What Is The Expected Consumption For 2021? With T …
The global Dexlansoprazole market is expected to surge at a steady CAGR in the coming years, states the latest QY Research report. The publication offers an insightful take on the historical data of the market and the milestones it has achieved. The report also includes an assessment of current market trends and dynamics, which helps in mapping the trajectory of the global Dexlansoprazole market. Analysts have used Porter’s five forces…
Ticlopidine Market Witness an Outstanding Growth and Strong Revenue by 2027 | ME …
Due to the increasing organic and inorganic expansion within the sector, the Ticlopidine Market is predicted to surge throughout the forecast period. In addition, the market is also on the increase, boosting the makers of generic anti-plates. It is also projected that the amount of funding that companies invest in for research and development will contribute to the income of the Ticlopidine Market in the future. Researchers now focus on…